|
|
|
Thorazine advertisement, 1968. Hospital & Community Psychiatry Vol. 19, No. 4. Profound calming... Stat. Thorazine® brand of chlorpromazine In acute psychic disturbance * Alcoholic agitation, delirium and vomiting. Before prescribing, see the complete prescribing information, including adverse effects reported with phenothiazine derivatives and symptoms and treatment of overdosage, in SK&F literature or PDR. The following is a brief precautionary statement. Contraindications: Comatose states or the presence of large amounts of C.N.S. depressants. Precautions: Potentiation of C.N.S. depressants may occur (reduce dosage of such agents when used concomitantly). Antiemetic effect may mask signs of overdosage of toxic drugs or obscure diagnosis of other conditions. Administer in pregnancy only when necessary for patient's welfare. Possibility of drowsiness should be kept in mind for patients who drive cars, etc. Adverse reactions: Drowsiness; dry mouth; nasal congestion; constipation and, on high dosages, adynamic ileus; amenorrhea; miosis; mild fever; weight gain; hypotensive effects, sometimes severe with I.M. administration; epinephrine effects may be reversed; dermatological reactions including photosensitivity (avoid undue exposure to the sun); extrapyramidal symptoms on high dosages (in rare instances, may persist); lactation and moderate breast engorgement (in females on high dosages); and less frequently, cholestatic jaundice (use cautiously in patients with liver disease). Adverse reactions occurring rarely, include: mydriasis; agranulocytosis; skin pigmentation, epithelial keratopathy, lenticular and corneal deposits (after prolonged substantial doses). Available: Tablets, 10 mg., 25 mg., 50 mg., 100 mg. and 200 mg.; Spansule® capsules, 30 mg., 75 mg., 150 mg., 200 mg. and 300 mg.; Injection, 25 mg./cc.; Syrup, 10 mg./5cc.; Concentrate, 30 mg./cc. © 1967, 1968 Smith, Kline & French Laboratories |